CLAIMS

1. Use of a CD96-inhibitory agent in the manufacture of a medicament for ~~A method of~~ reducing or relieving immune inhibition in a mammal, said ~~method~~ use including the step of at least partly inhibiting or reducing CD96 activity in one or more cells of the mammal to thereby relieve immune inhibition and/or enhance or restore immune surveillance in the mammal, wherein the step of at least partly inhibiting or reducing CD96 activity in the mammal includes a CD96-inhibitory agent to be administered to the mammal.

2. The ~~method~~ use of Claim 1, wherein the step of at least partly inhibiting or reducing CD96 activity in the mammal does not include, or at least depend upon killing of CD96-expressing cells in the mammal.

~~3. The method of Claim 1 or Claim 2, wherein the step of at least partly inhibiting or reducing CD96 activity in the mammal includes administering a CD96-inhibitory agent to the mammal.~~

~~4.~~3. The use ~~method~~ of Claim ~~3~~1, wherein the CD96-inhibitory agent binds or interacts with one or a plurality of external immunoglobulin-like domains of CD96.

~~5.~~4. The use ~~method~~ of Claim ~~3~~1, wherein the CD96-inhibitory agent binds or interacts with: one or a plurality of external immunoglobulin-like domains of CD96 selected from the group consisting of; domain 1; domain 2; domain 3; domain 1 and domain 2; domain 1 and domain 3: domain 2 and domain 3; and domain 1, domain 2 and domain 3.

~~6.~~5. The use ~~method~~ of Claim ~~4~~3 or Claim ~~5~~4, wherein the CD96-inhibitory agent binds or interacts with one or a plurality of external immunoglobulin-like domains of human CD96 isoform 2 (SEQ ID NO:2).

~~7.~~6. The use ~~method~~ of any one or Claims ~~3~~1-~~6~~5, wherein the CD96-inhibitory agent at least partly blocks or inhibits CD96 binding to CD 155 and/or intracellular signalling by CD96.

~~8.~~7. The use ~~method~~ of Claim ~~7~~6, wherein the CD96-inhibkory agent is an anti-CD96 antibody or antibody fragment.

~~9.~~8. The use ~~method~~ of any preceding claim which includes ~~administering~~ one or more other therapeutic agents to be administered.

~~10.~~9. The use ~~method~~ of Claim ~~9~~8, wherein the one or more other therapeutic agents include a chemotherapeutic agent and one or more antibodies or antibody fragments that bind PDI and/or CTLA4.

~~11.~~10. The use ~~method~~ of any preceding claim, which increases or enhances cytokine and/or chemokine expression and/or secretion by one or more cells in the mammal.

~~12.~~11. The use ~~method~~ of Claim ~~11~~10, wherein the cytokine and/or chemokines include MIP-1α, MIP-1β, RANTES, TNF-α and IFN-γ.

~~13.~~12. The use ~~method~~ of Claim ~~12~~11, wherein the cytokine is interferon γ (IFN-γ).

~~14.~~13. The use ~~method~~ of Claim ~~11~~10, Claim ~~12~~11 or Claim ~~13~~12, wherein the one or more cells are T cells, inclusive of $CD4^+$ and $CD8^+$ T cells, γδ T cells and NK T cells and natural killer (NK.) cells.

~~15.~~14. The use ~~method~~ of any preceding claim, which treats or prevents cancer or cancer metastasis in the mammal.

~~16.~~15. The use ~~method~~ of any preceding claim, which treats or prevents a viral infection in the mammal.

~~17.~~16. The use ~~method~~ of any preceding claim, wherein the mammal is a human.

~~18.~~17. A method of screening, designing, engineering or otherwise producing a CD96-inhibitory agent, said method including the step of determining whether a candidate molecule is capable of at least partly inhibiting or reducing CD96 activity to thereby relieve immune inhibition and/or enhance or restore immune surveillance in a mammal.

~~19.~~18. The method of Claim ~~18~~17 wherein the CD96-inhibitory agent binds or interacts with one or a plurality of external immunoglobulin-like domains of CD96.

~~20.~~19. The method of Claim ~~19~~18, wherein the CD96-inhibitory agent binds or interacts with one or a plurality of external immunoglobulin-like domains of CD96 selected from the group consisting of; domain 1; domain 2; domain 3; domain 1 and domain 2; domain 1 and domain 3: domain 2 and domain 3; and domain 1, domain 2 and domain 3.

~~21.~~20. The method of Claim ~~19~~18 or Claim ~~20~~19 wherein the CD96-inhibitory agent binds or interacts with one or a plurality of external immunoglobulin-like domains of human CD96 isoform 2 (SEQ ID NO:2).

~~22.~~21. The method of any one of Claims ~~18~~17-~~21~~20, wherein the CD96-mhibitory agent is an antibody or antibody fragment.

~~23.~~22. The method of any one of Claims ~~18~~17-~~22~~21, wherein the CD96-inhibitory agent is an anti-cancer agent.

~~24.~~23. The method of any one of Claims ~~15~~14-~~23~~22, wherein the CD96-inhibitory agent is an anti-viral agent.

~~25.~~24. The method of any one of Claims ~~18~~17-~~24~~23, wherein the mammal is a human.

~~26.~~25. A CD96-inhibitory agent screened, designed, engineered or otherwise produced according to the method of any one of Claims ~~18~~17-~~25~~24.

~~27.~~26. The CD96-inhibitoty agent of Claim ~~26~~ 25 for use according to ~~the method of~~ any one of Claims 1-~~17~~16.